Current literature suggests that transdermal fentanyl is efficacious in relieving cancer-related pain with less opioid-related constipation than morphine for patients in the palliative care setting. However, randomised controlled trials are needed to study the drug's efficacy compared with other level-three opioids that are used to manage cancer-related pain in palliative care.

We all have a role in preventing fentanyl patch tragedies.

The aim of the present study was to develop and investigate the feasibility of delivering Nebivolol as a transdermal patch by iontophoresis. The passive and electrically assisted transdermal delivery of Nebivolol hydrochloride by iontophoresis will improve the therapeutic efficacy and overcome the difficulties raised in oral drug delivery. Because of its extensive hepatic metabolism and low dos...

Monitoring fentanyl concentration in saliva and plasma may be useful in pharmacokinetic/pharmacodynamic studies. Salivettes(®) have been used widely for collecting saliva samples. However due to its lipophilicity, fentanyl adsorbs to the cotton dental bud (CDB) used in this device. Furthermore, due to dry mouth being a common adverse effect seen in patients treated with opioids, obtaining enoug...

INTRODUCTION Rivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first cholinesterase inhibitor to be available in the transdermal format. We aim to describe user experience and satisfaction with the rivastigmine patch, as well as any clinical changes perceived in patients. METHODS Observational, cross-sectional, multicentre study with 239 investigators and 1851 info...

The Transdermal Drug Delivery System (TDDS) is one of the novel routes for systemic delivery of drugs through intact skin. A transdermal patch (TP) is a medicated patch that is placed on skin for delivery of medication through skin into the blood stream. The aim of present study was to formulate and evaluate a Unani transdermal patch that could be used for antiemetic therapy. The incorporation ...

AIM A systematic review of chronic pain treatment with strong opioids (step 3 WHO pain ladder) and a comparison to a new drug recently approved for the treatment of severe chronic pain in Europe, tapentadol (Palexia, Nucynta*), were performed. METHODS Thirteen electronic databases were searched as well as a number of other sources from 1980 up to November 2010 for relevant randomized controll...